Henry Meds GLP-1vsIvim Health Compounded GLP-1

Henry Meds prescribes compounded versions of GLP-1 receptor agonists, primarily semaglutide (the molecule in Ozempic and Wegovy) and tirzepatide (in Mounjaro and Zepbound). These drugs mimic the gut hormone GLP-1 (tirzepatide also mimics GIP), which slows stomach emptying, signals fullness to the brain, and improves how the body regulates blood sugar and appetite. The result is reduced hunger, smaller portions, and weight loss. "Compounded" means a licensed pharmacy mixes the medication rather than it being a mass-produced, FDA-approved finished product; the FDA has warned that some compounders have used unapproved salt forms (such as semaglutide sodium or acetate) that differ from the base molecule in the approved drugs.

You take a weekly subcutaneous injection of compounded semaglutide (a GLP-1 receptor agonist) or compounded tirzepatide (a dual GIP/GLP-1 agonist). These slow gastric emptying and increase satiety signaling, reducing appetite and calorie intake. Ivim providers tailor your dose individually rather than using a fixed schedule, adjusting as tolerated.

Henry Meds has not published its own clinical trials; efficacy is inferred from studies of the same active molecules. In the pivotal STEP 1 trial (NEJM 2021, 1,961 adults over 68 weeks), once-weekly 2.4 mg semaglutide produced a mean 14.9% reduction in body weight versus 2.4% with placebo, and 86.4% of participants lost at least 5% of their body weight. Tirzepatide produced even larger average losses in its SURMOUNT program. Important caveat: compounded products are not FDA-approved and are not tested for the same bioequivalence, and Henry Meds' lower-strength and oral/sublingual formulations lack the trial evidence that supports the brand injectables, so individual results may differ and could be lower than the trial figures.

Ivim's compounded medications use the same active molecules as branded GLP-1 drugs. In STEP 1, branded semaglutide produced about 14.9% average weight loss over 68 weeks; in SURMOUNT-1, branded tirzepatide produced up to about 20.9% over 72 weeks. Compounded formulations are not separately FDA-tested, so these are reference points only. Individual results vary.

The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation, which are usually mild-to-moderate and worst during dose escalation. In STEP 1, about 4.5% of semaglutide users discontinued because of GI effects versus 0.8% on placebo. Serious but rarer risks include acute pancreatitis (severe abdominal pain), gallbladder disease, kidney injury from dehydration, and low blood sugar (especially when combined with other diabetes medications). All GLP-1 drugs in this class carry a boxed warning for thyroid C-cell tumors seen in rodents. The FDA has separately flagged compounded products for dosing errors and quality issues, including multiple adverse-event reports, some requiring hospitalization, tied to incorrect self-measured doses.

The most common effects are gastrointestinal (nausea, diarrhea, constipation, fatigue) and usually ease with gradual titration. Serious but uncommon risks include pancreatitis and gallbladder disease. As a compounded product, dosing-error and quality risks exist, so report unusual symptoms to your provider. This is educational information, not medical advice.

As of 2026, Henry Meds compounded injectable semaglutide runs roughly $297/month month-to-month, dropping to about $247/month on a 6-month plan and around $197/month on a 12-month prepay; oral and sublingual options are cheaper (often roughly $99-$249/month), and higher dose tiers typically add about $100/month (some tiers reach about $397/month). The price bundles provider visits, medication, and shipping with no separate membership fee. Compounded GLP-1s are essentially never covered by insurance and are paid out of pocket; by comparison, brand Wegovy or Zepbound can exceed $1,000/month without coverage. Note BBB complaints about auto-renewal billing, unexpected price increases, and refunds, so cancel before renewal and confirm current published pricing at signup.

Effective combined cost is about $150/month for semaglutide and ~$208/month for tirzepatide as of May 2026, built from a $75/mo membership (first month free) plus medication bundles ($379-$499 for semaglutide, $550-$900 for tirzepatide). HSA/FSA cards and Klarna financing are accepted. Compounded medication is not insurance-covered.

Generally aimed at adults seeking weight management who meet clinical criteria assessed during the telehealth intake, typically a BMI of 30 or higher, or 27 or higher with a weight-related condition such as high blood pressure, prediabetes, or high cholesterol. You must NOT use these drugs if you or a family member has a history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). They are contraindicated in pregnancy and breastfeeding, generally avoided with a history of pancreatitis, and require caution with gallbladder disease, diabetic retinopathy, or severe gastrointestinal disease. Your prescriber makes the final eligibility call. Anyone whose insurance covers FDA-approved Wegovy or Zepbound should weigh those first.

For US adults seeking medical weight management who pass Ivim's telehealth clinical evaluation. Not appropriate for people with a personal or family history of medullary thyroid carcinoma or MEN 2, or during pregnancy. State availability varies.